AAV‑IKV outer retinal transduction
AAV‑IKV enabled transgene delivery to photoreceptors and RPE from an intravitreal route in murine studies, with Nrf2 expression reducing oxidative stress markers in the retina.
Evidence base
Peer‑reviewed science supporting retinal delivery and ocular disease programs.
Visiogene’s programs are grounded in studies of retinal penetrating AAV, cell‑penetrating chaperone delivery, wet AMD biology, glaucoma biology, and protein/gene editing delivery.
Evidence themes
From delivery bottleneck to program biology.
The science package supports three major themes: delivery to ocular tissues, disease biology around decorin and TGFβ, and the ability to transport diverse cargo into retinal cells.
Nuc1 protein and large molecule delivery
Nuc1 was designed to bind retinal cell surface features and support delivery of cargo including proteins, antibodies, peptides, steroids, decorin, and AAV.
Decorin in wet AMD and glaucoma models
AAV‑IKV‑Decorin data support activity against CNV and fibrosis in wet AMD models and against TGFβ2‑driven IOP, fibrosis, and retinal ganglion cell loss in glaucoma models.
Selected publications and manuscripts
Research package.
Linked manuscripts are included in the site package under assets/papers/ for convenient review.
Retinal Penetrating Adeno‑Associated Virus
Describes AAV‑IKV design and delivery of transgenes to outer retinal targets following intravitreal injection in mice.
Cell‑Penetrating Chaperone Nuc1 for Small‑ and Large‑Molecule Delivery Into Retinal Cells and Tissues
Introduces Nuc1 as a chaperone for cargo delivery into retinal tissues without chemical conjugation.
Intravitreal AAV‑IKV Mediated Delivery of Decorin Inhibits CNV, Fibrosis, Inflammation and Elevates Autophagy
Supports the wet AMD program rationale using AAV‑IKV‑Decorin in a laser-induced CNV model.
AAV‑IKV Mediated Expression of Decorin Inhibits EMT and Fibrosis in a Murine Model of Glaucoma and AAV‑IKV Transduction in Non‑Human Primates
Supports anterior segment delivery, decorin activity in glaucoma biology, and initial non-human primate tolerability observations.
Protein and Gene Editing Delivery Studies
Supplementary research materials illustrating Nuc1-enabled delivery of Cre recombinase, Cas9 fusion protein, and Cas9 RNPs in ocular models.
Development posture
Preclinical and investigational.
All Visiogene product candidates are investigational. The current site language is intentionally oriented toward strategic and scientific audiences, not patients or prescribing physicians.
Delivery platform validation
AAV‑IKV and Nuc1 studies establish feasibility across retinal and anterior segment settings.
Disease model activity
Decorin programs apply the platform to wet AMD and glaucoma biology.
Translational expansion
Next steps include further characterization, manufacturing strategy, toxicology planning, and indication prioritization.
Scientific foundation
Review the supporting studies and translational plan.
Visiogene is advancing preclinical programs built from peer-reviewed retinal delivery research.